Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (171-180 of 352) with videos related to

Pageof 36
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 16, 2024
Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trialStefan Schreiber, Geert D'Haens, Fraser Cummings, et al.
Advances in Therapy|November 20, 2013
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategiesEnrique Grande, Michael C Kreissl, Sebastiano Filetti, et al.
World Journal of Gastroenterology|March 17, 2005
Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlationsPeter Laszlo Lakatos, Laszlo Lakatos, Ferenc Szalay, et al.
Inflammatory Bowel Diseases|February 13, 2019
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID RegistryEdward V Loftus, Walter Reinisch, Remo Panaccione, et al.
Journal of Crohn'S & Colitis|February 17, 2024
Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn's Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled TrialWalter Reinisch, Jean-Frederic Colombel, Geert R D'Haens, et al.
Journal of Crohn'S & Colitis|January 22, 2026
Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinibFernando Magro, Gerhard Rogler, Brian G Feagan, et al.
Advances in Therapy|March 9, 2018
Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical StudiesEdouard J Louis, Walter Reinisch, David A Schwartz, et al.
World Journal of Gastroenterology|February 16, 2026
Determination of correlation of clearance with clinical outcomes for inflammatory bowel diseaseDiane R Mould, Maximillian Kutschera, Christian Primas, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2014
Factors associated with short- and long-term outcomes of therapy for Crohn's diseaseWalter Reinisch, Jean-Frederic Colombel, William J Sandborn, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 1, 2024
Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease ProgressionNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Pageof 36

Showing results (171-180 of 352) with videos related to

Sort By:
Pageof 36
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 16, 2024
Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trialStefan Schreiber, Geert D'Haens, Fraser Cummings, et al.
Advances in Therapy|November 20, 2013
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategiesEnrique Grande, Michael C Kreissl, Sebastiano Filetti, et al.
World Journal of Gastroenterology|March 17, 2005
Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlationsPeter Laszlo Lakatos, Laszlo Lakatos, Ferenc Szalay, et al.
Inflammatory Bowel Diseases|February 13, 2019
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID RegistryEdward V Loftus, Walter Reinisch, Remo Panaccione, et al.
Journal of Crohn'S & Colitis|February 17, 2024
Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn's Disease [DIVERGENCE 2]: A Phase 2, Randomised, Placebo-controlled TrialWalter Reinisch, Jean-Frederic Colombel, Geert R D'Haens, et al.
Journal of Crohn'S & Colitis|January 22, 2026
Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinibFernando Magro, Gerhard Rogler, Brian G Feagan, et al.
Advances in Therapy|March 9, 2018
Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical StudiesEdouard J Louis, Walter Reinisch, David A Schwartz, et al.
World Journal of Gastroenterology|February 16, 2026
Determination of correlation of clearance with clinical outcomes for inflammatory bowel diseaseDiane R Mould, Maximillian Kutschera, Christian Primas, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2014
Factors associated with short- and long-term outcomes of therapy for Crohn's diseaseWalter Reinisch, Jean-Frederic Colombel, William J Sandborn, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 1, 2024
Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease ProgressionNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Pageof 36